• PDF / 170,227 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 64 Downloads / 119 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities: case report. A 56-year-old man developed diarrhoea, anorexia, thrombocytopenia, hyperbilirubinaemia, corneal and lacrimal duct disorders and peripheral neuropathy during treatment with gimeracil/oteracil/tegafur, oxaliplatin and bevacizumab for peritoneal dissemination of colon cancer [not all routes, dosages and outcomes stated]. The man, underwent sigmoid colectomy after diagnosis of sigmoid colon cancer. Nine months after the sigmoid colectomy, he was diagnosed with recurrent peritoneal dissemination of colon cancer. He started receiving systemic chemotherapy with IV bevacizumab infusion 7.5 mg/kg followed by IV oxaliplatin infusion 130 mg/m2 on day 1 of a 3 week cycle. He was also prescribed oral gimeracil/oteracil/tegafur [S-1] 120 mg/day twice daily from day 1 of the cycle for 2 weeks. However, during the first cycle, he developed severe diarrhoea and anorexia that required unspecified infusion treatment. The man’s second cycle was delayed by 2 weeks. The man’s second cycle was resumed with reduced dose of gimeracil/oteracil/tegafur; however, on day 4 of the second cycle, he again developed anorexia and severe diarrhoea. Therefore, gimeracil/oteracil/tegafur was stopped and he was hospitalised for 2 weeks for the management of adverse effects. During the third cycle, gimeracil/oteracil/tegafur and oxaliplatin were administered on alternate days. Thereafter, he was able to continue the chemotherapy without any adverse effects. After 4 cycles, exams showed complete disappearance of all the tumours. After 8 cycles, he developed grade 3 peripheral neuropathy. Therefore, he was switched to maintenance chemotherapy including alternate day administration of gimeracil/oteracil/tegafur plus bevacizumab. The maintenance chemotherapy was discontinued after a total of 17 cycles due to related adverse events corneal and lacrimal duct disorder, thrombocytopenia, and hyperbilirubinaemia. Thereafter, he remained in a complete remission for 5 years with no recurrence. Nitori N, et al. Complete remission of peritoneal dissemination of colon cancer by alternate-day S-1 and oxaliplatin plus bevacizumab treatment and maintenance chemotherapy comprising alternate-day S-1 plus bevacizumab: A case report. Molecular and Clinical Oncology 10: 270-274, No. 2, Feb 2019. Available from: URL: http:// 803498354 doi.org/10.3892/mco.2018.1791

0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 29 Aug 2020 No. 1819